TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00420927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
Study: NCT03689946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-NaF PET
Description: 18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CCTA
Description: CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque
Description: contrast agent for CCTA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: beta blocker to optimize heart rate during CCTA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: premedication for CCTA
Study: NCT01010945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: administered intravenously
Study: NCT02893969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rest
Description: Complete physical rest until asymptomatic.
Study: NCT01627561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: 2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix
Description: 1 dose administered intramuscularly in the deltoid muscle of the left arm at Day 0.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix
Description: 1 dose administered intramuscularly in the deltoid muscle of the left arm at Month 6.
Study: NCT03422549

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drager VN500 Ventilator
Description: This ventilator is capable of providing both CPAP and NHFOV support.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drager VN500 Ventilator
Description: This ventilator is capable of providing both CPAP and NHFOV support.
Study: NCT00420927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
Study: NCT00744380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
Study: NCT00036855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSC transplantation
Study: NCT01511692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg/day injected subcutaneously for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo, injected subcutaneously for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Dose individually adjusted, administered orally for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glimepiride
Description: Dose individually adjusted, administered orally for 4 weeks
Study: NCT04453345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide + prednisone + methotrexate
Description: thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.
Study: NCT02158000

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group A
Description: one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
Study: NCT02453139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 month supervised and home based aerobic exercise intervention
Study: NCT02662283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reh-acteoside
Description: Oral take and reh-acteoside (0.4g bid) for 8 weeks
Study: NCT02937090

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood sample will be drawn from participants at study entry.

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood sample will be drawn from participants at study entry.

Intervention type: OTHER
Intervention: Stool collection
Description: Stool will be collected from participants at study entry.

Intervention type: OTHER
Intervention: Stool collection
Description: Stool will be collected from participants at study entry.
Study: NCT00908050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally.
Study: NCT00036855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSC transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00908050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo arm
Description: Placebo comparator
Study: NCT01685060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
Study: NCT00036855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01794663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPN-305
Description: Intravenous infusion for 1 hour at start of transplant procedure
Study: NCT02802735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablet for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet for oral administration
Study: NCT00854984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Life to the Full
Description: A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
Study: NCT00928499

Intervention type: DEVICE
Group type: OTHER
Intervention: Interstim (SNS)
Description: Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy

Intervention type: DEVICE
Group type: OTHER
Intervention: Interstim (SNS)
Description: Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
Study: NCT02094196

Intervention type: OTHER
Intervention: Alcohol detoxification
Description: Detoxified alcohol- dependent patients in an inpatient setting
Study: NCT03797157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: H2MF
Description: H2MF is a human milk-based breastmilk fortifier for preterm infants

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bovine milk-based fortifier
Description: Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
Study: NCT02049294

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab (Xolair)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03701061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine
Description: A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal Influenza Vaccine
Description: A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
Study: NCT02949414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells
Description: The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
Study: NCT01624974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: MK-1029 150 mg tablets taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: MK-1029 150 mg tablets taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets (matching the MK-1029 150 mg tablets) QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets (matching the MK-1029 150 mg tablets) QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast (ML)
Description: ML 10 mg tablets QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast (ML)
Description: ML 10 mg tablets QD
Study: NCT03114670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells
Description: a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
Study: NCT00869375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular peripheral intervention
Description: Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular peripheral intervention
Description: Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
Study: NCT02597686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SD-PB training
Study: NCT04176328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.
Description: Teicoplanin Sandoz administered by inhalation (aerosol).
Study: NCT02649075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serum-derived Bovine Immunoglobulin / Protein Isolate
Description: Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
Study: NCT01841086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UI03SPG300CT
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UI03SPG300CT
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day
Study: NCT03581565

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zinc polycarboxylate (with the requirements of ISO 9917)
Description: intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zinc polycarboxylate (with the requirements of ISO 9917)
Description: intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: zinc polycarboxylate (with the requirements of ISO 9917)
Description: intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
Study: NCT04154111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TBS to the vmPFC
Description: This will be delivered with the Magventure Magpro system; double blinded

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS to the vmPFC
Description: The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TBS to the dlPFC
Description: This will be delivered with the Magventure Magpro system (double blinded).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS to the dlPFC
Description: The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the coil.
Study: NCT02811081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive Deflation
Description: In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline Instillation
Description: In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline Instillation + Pulmonary Recruitment
Description: In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
Study: NCT02513355

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Changchun marina
Description: 25mg/m2,d1 and d8,q21d×4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80mg/m2,d1, q21d×4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80mg/m2,d1, q21d×4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: 135-175mg/m2,d1,q21d×4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parapl
Description: AUC=5-6,d1,q21d×4
Study: NCT03177473

Intervention type: DEVICE
Intervention: CervicalStim bone growth stimulator
Description: Orthofix CervicalStim bone growth stimulator
Study: NCT01116128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: 100 mg QD continuously (from day 1 to day 28)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 0,18 mg/Kg/day from day 1 to day 4 for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
Study: NCT02385292

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculeve Intranasal Lacrimal Neurostimulator
Description: The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal Lacrimal Neurostimulator
Description: The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
Study: NCT03934515

Intervention type: OTHER
Intervention: etCO2
Description: At the end of the procedure, therefore, for each patient two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values at the endotracheal level and the esophageal level values. The authors will find the threshold value of etCO2 collected when the NGT is well positioned in trachea. The study manager is not directly involved in the measurement and recording of etCO2 values.

Intervention type: OTHER
Intervention: pH
Description: At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at esophageal level and a value at the gastric level. The authors will find the threshold value of pH collected when the NGT is positioned in the esophagus and in the stomach. The study manager is not directly involved in the measurement and recording of pH values.
Study: NCT03037333

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transvenous cardiac pacing guided by fluoroscopy
Description: Transvenous cardiac estimulation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transvenous cardiac pacing guided by ECG/ECHO
Description: Transvenous cardiac estimulation
Study: NCT01320033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD2475/101 40 mg
Description: Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 mg
Description: Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.
Study: NCT02045979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Description: BI 695501 single s.c. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab-EU source
Description: adalimumab-EU source single s.c. injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab-US source
Description: adalimumab-US source single s.c. injection.